Clinical Trial Update: A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Roxadustat to recombinant human Erythropoietin and its effect on oral iron absorption in Chinese patients with anemia of chronic kidney …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• Recombinant human erythropoietin (erythropoietin)
• Roxadustat (roxadustat)

Snippet

Sponsor: AstraZeneca | Conditions: Anemia of Chronic Kidney Disease | Phase 4 | Status: COMPLETED | Results posted: 2024-04-22